Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (5)
  • Until platform closure (19)
Poster categories
  • Thematic Poster Session (27)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • x L-TPS04 (13)
  • L-TPS05 (10)
  • L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • x TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
27 results
Thumbnail

D1.227 - Nanobody-based anti-FcεRI antibodies for therapeutic targeting of the IgE-FcεRI complex

Thumbnail

D1.228 - Mitochondrial Epigenetic Programming: A Unifying Mechanism Linking Environmental Stress, Epithelial Barrier Dysfunction, and Allergy

Thumbnail

D1.229 - Real-life observational study on allergen-specific Immunotherapy with double-polymerized allergoids (Modigoid Cup a1) in patients allergic to Cupressus Arizonica pollen

Thumbnail

D1.218 - Effects of butyrylated high amylose maize starch (HAMSB) as an adjuvant for oral immunotherapy

Thumbnail

D1.219 - Efficacy and Safety of 300 IR Liquid Sublingual Immunotherapy in Allergic Asthma: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Thumbnail

D1.221 - Identification of IgE epitopes of major ragweed pollen allergens (Amb a 1 and Amb a 11)

Thumbnail

D1.222 - Production of Bet v 1-specific IgG antibodies in mice immunized with the recombinant vaccine ABP-Vax

Thumbnail

D1.223 - TNFR2 regulates early PD-L1/PD-L2 induction and Th1-associated cytokine responses during the early events of Allergen-Specific Immunotherapy (AIT) in a preclinical model

Thumbnail

D1.224 - Rational Design of a T-Cell Epitope-Based Chimeric Allergen from Dermatophagoides pteronyssinus Toward Precision Immunotherapy

Thumbnail

D1.225 - Long-term adherence to seasonal allergen immunotherapy: a 3-year (22/23-24/25) retrospective study on 174 patients

Thumbnail

D1.226 - Allergen Immunotherapy Preferences by Patient in Some Arabic countries: The CHOICE-Middle East Study

Thumbnail

D1.230 - Efficacy and Safety of Hymenoptera Venom Immunotherapy in a Patient with Systemic Mastocytosis

Thumbnail

D1.231 - Endotype-Guided Management of Allergic Asthma in a Pediatric Athlete: Impact of Sublingual Immunotherapy

Thumbnail

D2.216 - Effectiveness and safety of subcutaneous immunotherapy with Depigmented-Polymerized Cat Extract: real-world clinical evidence

Thumbnail

D2.217 - Structured Follow-Up Intervals Enhance Adherence to Sublingual Immunotherapy in Patients with Allergic Rhinitis: Real-World Evidence from a Stepwise Approach

Thumbnail

D2.218 - Effectiveness of the 300IR house dust mite sublingual tablet according to the patients’ sensitisation and allergy profile in the real-world, non-interventional VORAN study

Thumbnail

D2.219 - Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis

Thumbnail

D2.222 - A real-world observational study following the first year of SQ grass or SQ tree SLIT-tablet treatment to evaluate persistence and adherence in routine clinical practice among general practitioners in Norway

Thumbnail

D2.225 - Characterizing skin-resident antigen presenting cell responses to plant-based Fel d 1 Bioparticles

Thumbnail

D2.226 - Evaluation of the Immunogenicity and Stability of an Aluminum-Adsorbed Allergen Immunotherapy Using Specific IgG Titration in a Murine Model

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM